Meeting
2023 ASCO Annual Meeting
Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis.
Authors
Xavier Garcia del Muro
Medical Oncology. Institut Català d'Oncologia (ICO) L'Hospitalet del Llobregat, Barcelona, Spain
Xavier Garcia del Muro , M. Andres Cuellar , Pablo Maroto-Rey , Patrizia Giannatempo , Daniel Castellano , Andrea Necchi , Miguel Ángel Climent , Begoña Pérez Valderrama , Alfonso Gomez De Liano Lista , David Molina , Leonardo Mina , Daniel Alcalá-López , Miguel Sampayo , David Paez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Penile Cancer
Clinical Trial Registration Number
NCT04231981
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5043)
DOI
10.1200/JCO.2023.41.16_suppl.5043
Abstract #
5043
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS.
First Author: Xavier Garcia del Muro
Poster
2020 ASCO Virtual Scientific Program
Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study.
First Author: Sara Lonardi
Poster
2015 ASCO Annual Meeting
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).
First Author: David R. Spigel
First Author: Igor Tsaur